PEXA-VEC Emerging Drug Insight

“PEXA-VEC Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about PEXA-VEC for Oncolytic Virus Therapies (OVTs) in the seven major markets. A detailed picture of the PEXA-VEC for  OVTs in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the PEXA-VEC for OVTs. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the PEXA-VEC market forecast analysis for OVTs in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in OVTs.

Drug Summary

SillaJen’s lead investigational product PEXA-VEC, also known as JX-594, is a Wyeth strain vaccinia virus engineered to lyse tumor cells and stimulate antitumor immunity directly. The company believes that Pexa-Vec acts in three ways:

• By infecting and selectively replicating cancer cells and causing lysis
• Reducing the blood supply to tumors through infection of tumor associate vasculature
• By activating the body’s immune system to recognize and kill tumor cells

While the VV is inherently selective for cancer, Pexa-Vec was engineered for even superior cancer selectivity by exploiting the genetic changes that are hallmarks of cancer. Pexa-Vec replication and spread depend on activating the EGFR/Raf/Ras signaling, a pathway frequently activated in cancer, and high cellular levels of TK found in proliferating cancer cells. The viral TK gene has been deactivated in Pexa-Vec so the virus cannot replicate efficiently in normal cells. Pexa-Vec is also engineered to express the potent immune stimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), which may stimulate a tumor-specific immune response.

Currently, intratumoral Pexa-Vec is being investigated in multiple trials for different cancers. Additionally, some trials are evaluating this drug in a formulation like IV. For instance, in August 2017, the company entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the NIH, to develop a combination therapy for colorectal cancer (CRC) in which Pexa-Vec was administered intravenously.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the PEXA-VEC description, mechanism of action, dosage and administration, research and development activities in OVTs.
• Elaborated details on PEXA-VEC regulatory milestones and other development activities have been provided in this report.
• The report also highlights the PEXA-VEC research and development activities in OVTs across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around PEXA-VEC.
• The report contains forecasted sales of for OVTs till 2032.
• Comprehensive coverage of the late-stage emerging therapies for OVTs.
• The report also features the SWOT analysis with analyst views for PEXA-VEC in OVTs.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

PEXA-VEC Analytical Perspective by DelveInsight

In-depth PEXA-VEC Market Assessment

This report provides a detailed market assessment of PEXA-VEC for OVTs in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

PEXA-VEC Clinical Assessment

The report provides the clinical trials information of PEXA-VEC for OVTs covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for OVTs is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence PEXA-VEC dominance.
• Other emerging products for OVTs are expected to give tough market competition to PEXA-VEC and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of PEXA-VEC in OVTs.
• Our in-depth analysis of the forecasted sales data of PEXA-VEC from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PEXA-VEC in OVTs.

Key Questions

• What is the product type, route of administration and mechanism of action of PEXA-VEC?
• What is the clinical trial status of the study related to PEXA-VEC in OVTs and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PEXA-VEC development?
• What are the key designations that have been granted to PEXA-VEC for OVTs?
• What is the forecasted market scenario of PEXA-VEC for OVTs?
• What are the forecasted sales of PEXA-VEC in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to PEXA-VEC for OVTs?
• Which are the late-stage emerging therapies under development for the treatment of OVTs?